# Genmab

Source: https://onco.cc/companies/genmab/  
OnCo record `genmab` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Genmab is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly, and (via ProfoundBio) rinatabart sesutecan.

## Summary

Genmab, based in Copenhagen and listed as GMAB, is the Danish antibody engineering company behind the DuoBody platform, Tivdak, Epkinly and, through ProfoundBio, rinatabart sesutecan. Its own products are tisotumab vedotin, epcoritamab, a CD20 by CD3 bispecific, rinatabart sesutecan, a folate receptor alpha ADC in the RAINFOL-01 phase 3, and acasunlimab, a PD-L1 by 4-1BB bispecific, while its DuoBody technology underlies teclistamab, talquetamab and amivantamab, and daratumumab and ofatumumab are also linked. OnCo links it to cervical and endometrial cancer, lymphoma and head and neck cancer, and to the LiGeR-HN1 trial. Whether a royalty-rich platform company can become a fully commercial oncology business is the open question. Tisotumab vedotin has its own page.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Copenhagen
- Type: biotech
- Website: https://www.genmab.com
- Ticker: GMAB

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Genmab
- Official website: https://www.genmab.com

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- drugs: [Acasunlimab](https://onco.cc/drugs/acasunlimab/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [MCLA-129](https://onco.cc/drugs/mcla-129/), [Ofatumumab](https://onco.cc/drugs/ofatumumab/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/), [Rinatabart sesutecan](https://onco.cc/drugs/rinatabart-sesutecan/), [Tisotumab vedotin](https://onco.cc/drugs/tisotumab-vedotin/)
- companies: [Medicxi](https://onco.cc/companies/medicxi/), [ProfoundBio](https://onco.cc/companies/profoundbio/)
- trials: [A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P](https://onco.cc/trials/nct06496178/), [A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors](https://onco.cc/trials/nct03526835/), [A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcita](https://onco.cc/trials/nct06508658/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th](https://onco.cc/trials/nct05201248/), [A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl](https://onco.cc/trials/nct05283720/), [A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refr](https://onco.cc/trials/nct05451810/), [A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China](https://onco.cc/trials/nct07226752/), [An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Can](https://onco.cc/trials/nct07604766/), [Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors](https://onco.cc/trials/nct03485209/), [EPCORE DLBCL-1](https://onco.cc/trials/epcore-dlbcl-1/), [EPCORE DLBCL-2](https://onco.cc/trials/epcore-dlbcl-2/), [EPCORE NHL-1](https://onco.cc/trials/epcore-nhl-1/), [GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors](https://onco.cc/trials/nct04083599/), [innovaTV 301 / ENGOT-cx12 / GOG-3057](https://onco.cc/trials/innovatv-301/), [LiGeR-HN1](https://onco.cc/trials/liger-hn1/), [Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combina](https://onco.cc/trials/nct04868877/), [RAINFOL-01 (Rina-S)](https://onco.cc/trials/rainfol-01/), [Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome](https://onco.cc/trials/nct04623541/), [Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer](https://onco.cc/trials/nct05117242/), [Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)](https://onco.cc/trials/nct04663347/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metast](https://onco.cc/trials/nct07775287/), [Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorecta](https://onco.cc/trials/nct07702032/), [Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ](https://onco.cc/trials/nct06191744/), [Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease ](https://onco.cc/trials/nct05409066/), [Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer](https://onco.cc/trials/nct07166094/), [Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer](https://onco.cc/trials/nct07288177/), [Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Re](https://onco.cc/trials/nct07225270/), [Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or](https://onco.cc/trials/nct07564141/), [Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer](https://onco.cc/trials/nct06619236/), [Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)](https://onco.cc/trials/nct04542824/), [Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)](https://onco.cc/trials/nct06635824/)
- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/genmab.json